Onward Therapeutics Expands Global Presence With Headquarters in Taiwan Onward Therapeutics announces the completion of a share exchange, establishing its global headquarters in Taiwan to enhance its operational efficiency and growth.

Onward Therapeutics Expands Global Presence With Headquarters in Taiwan #Taiwan #Taipei #biotechnology #Onward_Therapeutics

Onward Therapeutics Partners with Institut du Cancer for Major Onco-Metabolism Licensing Deal Onward Therapeutics has signed a worldwide license agreement with Institut du Cancer de Montpellier to advance their innovative Onco-Metabolism program, aimed at enhancing cancer treatment.

Onward Therapeutics Partners with Institut du Cancer for Major Onco-Metabolism Licensing Deal #Switzerland #Onward_Therapeutics #Epalinges #Institut_du_Cancer #Onco-Metabolism

Onward Therapeutics Receives EMA Approval to Begin Clinical Trials for Novel NK Cell Therapy in Cancer Treatment Onward Therapeutics has gained EMA approval for its subsidiary Emercell to conduct clinical trials for its innovative NK cell therapy, OT-C001, targeting cancer.

Onward Therapeutics Receives EMA Approval to Begin Clinical Trials for Novel NK Cell Therapy in Cancer Treatment #Switzerland #Onward_Therapeutics #Emercell #OT-C001 #Epalinges